Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Sutimlimab for cold agglutinin disease: an updated perspective from approval to real-world clinical treatment.

Expert review of hematology·2026
Same author

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

American journal of hematology·2026
Same author

Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape.

Clinical advances in hematology & oncology : H&O·2025
Same author

Monotherapy with upstream or alternative pathway inhibitors.

Clinical advances in hematology & oncology : H&O·2025
Same author

Dual therapy: danicopan as add-on therapy to C5 inhibitors.

Clinical advances in hematology & oncology : H&O·2025
Same author

Practical approach to managing PNH: Q&A.

Clinical advances in hematology & oncology : H&O·2025

Related Experiment Video

Updated: Jul 28, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Complement-directed therapy for cold agglutinin disease: sutimlimab.

Catherine M Broome1

  • 1Division of Hematology, MedStar Georgetown University Hospital, Washington, DC, USA.

Expert Review of Hematology
|May 31, 2023
PubMed
Summary

Sutimlimab offers a new treatment for cold agglutinin disease (CAD), a rare autoimmune disorder. This therapy effectively reduces red blood cell destruction and improves patient well-being.

Keywords:
Cold agglutinin diseaseComplement C1sComplement-directed therapiesHemolysisQuality of lifeSutimlimab

More Related Videos

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K
Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.2K

Related Experiment Videos

Last Updated: Jul 28, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K
Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.2K

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia characterized by IgM antibodies targeting red blood cells.
  • Hemolysis in CAD is driven by the classical complement pathway activated by IgM-antigen complexes.

Approach:

  • This review details the drug profile of sutimlimab, a targeted therapy for CAD.
  • Key efficacy and safety data from Phase 3 studies supporting sutimlimab's approval are summarized.

Key Points:

  • Sutimlimab directly inhibits classical complement pathway activation, addressing the underlying mechanism of CAD.
  • The drug demonstrates rapid and sustained improvements in hemoglobin levels and hemolytic markers.
  • Sutimlimab also yields meaningful improvements in patient-reported fatigue and quality of life.

Conclusions:

  • Sutimlimab provides an approved therapeutic option for CAD management, improving clinical outcomes.
  • Its benefits extend beyond hemolysis inhibition to enhance overall patient well-being.
  • Real-world evidence from the CADENCE registry will further assess sutimlimab's effectiveness and safety.